Antimicrobial agents for the dermatologist. II. Macrolides, fluoroquinolones, rifamycins, tetracyclines, trimethoprim-sulfamethoxazole, and clindamycin

Journal of the American Academy of Dermatology

Volumn 37, Issue 3 I, 1997, Pages 365-381

  Epstein, M E ^a   Amodio Groton, M ^a   Sadick, N S ^a  

^a FACP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; CARBAMAZEPINE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DEMECLOCYCLINE; DIRITHROMYCIN; DOXYCYCLINE; ENOXACIN; ERYTHROMYCIN; LEVOFLOXACIN; LOMEFLOXACIN; MACROLIDE; METHYLPREDNISOLONE; MINOCYCLINE; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; OXYTETRACYCLINE; PHENYTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; SPARFLOXACIN; TETRACYCLINE DERIVATIVE; THEOPHYLLINE; UNINDEXED DRUG; WARFARIN;

ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; DERMATOLOGY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG INDICATION; DRUG MIXTURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MEDICAL SPECIALIST; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION;

EID: 0030884921     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(97)70135-X     Document Type: Article

References (181)

1. JM McGuire RL Bunch RC Anderson Ilolycin, a new antibotic Antibiot Chemother 2 1952 281 283
2. JE Washington WR. Wilson Erythromycin: a microbiological and clinical perspective after 30 years of clinical use May Clin Proc 60 1985 189 203
3. AS. Malamborg The renaissance of erythromycin J Antimicrob Chemother 18 1986 293 295
4. SC Piscitelli LH Danziger KA. Rodvold Clarithro-mycin and azithromycin: new macrolide antibiotics Clin Pharm 11 1992 137 152
5. N Bahal MC. Nahata The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin and roxithromycin Ann Pharmacother 26 1992 46 55
6. RN Brogden DH. Peters Dirithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy Drugs 48 1994 599 616
7. D. Schlossberg Azithromycin and clarithromycin Med Clin North Am 79 1995 803 815
8. MG Sturgill RP. Rapp Clarithromycin: a review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles Ann Pharmacother 26 1992 1099 1108
9. J Retsema A Girard W Schelkly Spectrum and mode of action of azithromycin (CP-662,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms Antimicrob Agents Chemother 31 1987 1939 1947
10. PB Fernandes R Bailer R Swanson In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide Antimicrob Agents Chemother 30 1986 865 873
11. DJ Hardy RN Swanson RA Rode Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans Antimicrob Agents Chemother 34 1990 1407 1413
12. AL Barry RN Jones C. Thornsberry In vitro activities of azithromycin (CP62, 993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin and clindamycin Antimicrob Agents Chemother 32 1988 752 754
13. WR Bowie CE Shaw GW Chan In vitro activity of RO 15-8074, RO 19-5247, A56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis Antimicrob Agents Chemother 31 1987 470 472
14. KB Waites GH Cassell KC Canupp In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones Antimicrob Agents Chemother 32 1988 1500 1502
15. DJ Hardy DM Hensey JM Beyer Comparative in vitro activities of new 14-, 15- and 16-membered macrolides Antimicrob Agents Chemother 32 1988 1710 1719
16. NX Chin NM Neu P Labthavikel Activity of A-56268 compared with that of erythromycin and oral agents against aerobic and anaerobic bacteria Antimicrob Agents Chemother 31 1987 463 466
17. KT Dunkin S Jones AJ. Howard The in vitro activity of CP-62,993 against Haemophilus influenzae, Branhamaella catarrhali, Staphylococci, and Streptococci J Antimicrob Chemother 21 1988 405 411
18. L Slaney H Chubb A Ronald In vitro activity of azithromycin, erythromycin, ciprofloxacin and norfloxacin against Neisseria gonorrhoeae, Haemophilus ducreyi , and Chlamydia trachomatis J Antimicrob Chemother 25 Suppl A 1990 1 5
19. MD Kitzis FW Goldstein M Miegi In vitro activity of azithromycin against various gram-negative bacilli and anaerobic bacteria J Antimicrob Chemother 25 Suppl A 1990 15 18
20. RH Gelber P Sui M Tsang Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice Antimicrob Agents Chemother 35 1991 760 763
21. C Perronne A Gikas C Truffot-Pernot Activities of sparfloxacin, azithromycin, temafloxacin and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages Antimicrob Agents Chemother 35 1991 1356 1359
22. CA Benson JJ. Ellner Mycobacterium avium complex infection and AIDS: advances in theory and practice Clin Infect Dis 17 1993 7 20
23. J Fernandez-Martin C Leport P Morlat Pyrimethamine-clarithromycin combination for therapy of acute toxoplasma encephalitis in patients with AIDS Antimicrob Agents Chemother 35 1991 2049 2052
24. RF Wynn CLS Leen RP. Brettle Azithromycin for cerebral toxoplasmosis in AIDS [letter] Lancet 341 1993 243 244
25. WL Peterson DY Graham B Marshall Clarithromycin as monotherapy for eradication of Helicobacter pylori : a randomized, double-blind trial Am J Gastroenterol 88 1993 1860 1864
26. M Deiriennic JP. Escande Dirithromycin in the treatment of skin and skin structure infections J Antimicrob Chemother 31 Supp C 1993 159 168
27. A. Lassus Comparative studies of azithromycin in skin and soft tissue infections and sexually transmitted infections by Neisseria and Chlamydia species J Antimicrob Chemother 25 Suppl A 1990 115 121
28. VJ Northcutt JC Craft P. Pichotta Safety and efficacy of clarithromycin (C) compared to erythromycin (E) in the treatment (tx) of bacterial skin or skin structure infections (SSSIs) [abstract 1339]. Program and Abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta 1990
29. LC Parish the Clarithromycin Study Group Clarithromycin in the treatment of skin and skin structure infections: two multicenter clinical studies Int J Dermatol 32 1993 528 532
30. P Dilorenzo C Shupbach J Salisbury Dirithromycin (D) 5 days versus erythromycin base (E) 7 days in skin and soft tissue infections (abstract 402). Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans 1993 192
31. BJ Luft RJ Dattwyler RC. Johnson Azithromycin compared with amoxicillin in the treatment of erythema migrans: a double-blind, randomized controlled trial Ann Intern Med 124 1996 785 791
32. N Franck A Cabié B Villette B Amos Treatment of Mycobacterium chelonae – induced skin infection with clarithromycin J Am Acad Dermatol 28 1993 1019 1021
33. JT Webb RE. Johnson New treatments for Chlamydia trachomatis genital infection Clin Infect Dis 20 Suppl 1 1995 S66 S71
34. GE Stein DH. Havlichek The new macrolide antibiotics: azithromycin and clarithromycin Postgrad Med 92 1992 269 280
35. O Steingrimsson JH Olafsson H Thorarinssin Single dose azithromycin treatment of gonorrhea and infections caused by C. trachomatis and U. urealyticum in men Sex Transm Dis 21 1984 43 46
36. DH Martin TF Mroczkowski ZA Dalu Controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis N Engl J Med 327 1992 921 925
37. DE Amacher SJ Schomaker JA. Retsema Comparison of the effects of the new azalide antibiotic azithromycin, and erythromycin estolate on rat liver cytochrome P-450 Antimicrob Agents Chemother 35 1991 1186 1190
38. T Lindstrom B Hanssen S. Wrighton Cytochrome P450 complex formation by dirithromycin and other macrolides in rat and human livers Antimicrob Agents Chemother 37 1993 265 269
39. Product information. BiaxinR, clarithromycin 1995 Abbott Laboratories North Chicago (IL)
40. S Harris D Hilligoss P Colandelo Azithromycin and terfenadine: lack of drug interaction Clin Pharmacol Ther 58 1995 310 315
41. PK Honig D Wortham K Zamani Effects of erythromycin, clarithromycin, and azithromycin on the pharmacokinetics of terfenadine [abstract PI106] Clin Pharm Ther 53 1993 161
42. DH Peters SP. Clissold Clarithromycin, a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential Drugs 44 1992 117 164
43. B Petty M Polis S Haneiwick Pharmacokinetic assessment of clarithromycin plus zidovudine in HIV patients [abstract 24]. Presented at the 32nd Interscience Conference on Antimicrobial Agents Chemotherapy, Anaheim, Calif 1992
44. E Vance M Watson-Bitar L Gustovson Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS Antimicrob Agents Chemother 39 1995 1355 1360
45. TG Gillum VC Bruzzese DS Israel Effect of multiple oral doses of clarithromycin (clary) on the pharmacokinetics of 2′-3′-dideoxyinosine (ddI) in patients infected with HIV [abstract]. Presented at the First National Conference on Human Retroviruses and Related Infections, Washington, DC 1993
46. Datri 001 Study Group Clarithromycin (CL) plus rifabutin (RFB) for MAC prophylaxis evidence of drug interaction [abstract]. Presented at the First National Conference on Human Retroviruses and Related Infections, Washington, DC 1993
47. G Foulds DM Hilligoss EB Henry The effects of an antacid or cimetidine on the serum concentrations of azithromycin J Clin Pharmacol 31 1991 164 167
48. GD Sides PM. Conforti Safety profile of dirithromycin J Antimicrob Chemother 31 Suppl C 1992 175 185
49. K. Jacobson Clinical efficacy of dirithromycin in pneumonia J Antimicrob Chemother 31 Suppl C 1993 121 129
50. GY Lester EJ Froelich MD Gruett 1-8-naphthyridine derivatives: a new class of chemotherapeutic agents J Med Pharm Chem 5 1962 1063
51. DTW Chu PB. Fernandes Structure activity relationships for the fluoroquinolones Antimicrob Agents Chemother 33 1989 131 135
52. B Suh B. Lorber Quinolones Med Clin North Am 79 1995 869 894
53. DC Hooper JS. Wolfson Fluoroquinolone antimicrobial agents N Engl Med 324 1991 384 394
54. JS Wolfson DC. Hooper Fluoroquinolone antimicrobial agents Clin Microbiol Rev 2 1989 378 424
55. HM Crowe R. Quintilliani Antibiotic formulary selection Med Clin North Am 79 1995 463 476
56. A. Fitton The quinolones: an overview of their pharmacology Clin Pharmacokinet 22 1992 1 11
57. N-X Chin HC. Neu Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria Antimicrob Agents Chemother 25 1984 319 326
58. CH Collins AHC. Uttley In vitro susceptibility of mycobacteria to ciprofloxacin J Antimicrob Chemother 16 1985 575 580
59. TM Hooton TA. Tartaglione The role of fluoroquinolones in sexually transmitted diseases Pharmacotherapy 13 1993 189 201
60. RA. Husain Disturbing susceptibility pattern for ciprofloxacin [letter] Am J Hosp Pharm 48 1991 1892
61. T Jensen SS Pederson CH Hielson The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis J Antimicrob Chemother 20 1987 585 594
62. AS Bayer L Hirano J. Yih Development of β-lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis Antimicrob Agents Chemother 32 1988 231 235
63. WJ. Mogabgab Recent developments in the treatment of sexually transmitted diseases Am J Med 91 Suppl 6A 1991 140S 144S
64. M. Neuman Clinical pharmacokinetics of the newer antimicrobial 4-quinolones Clin Pharmacokinet 14 1988 96 121
65. S Adhami R Wise D Wiston The pharmacokinetics and tissue penetration of norfloxacin J Antimicrob Chemother 13 1984 87 92
66. JP Fillastre A Leroy B Moulin Pharmacokinetics of quinolones in renal insufficiency J Antimicrob Chemother 26 Suppl B 1990 51 60
67. DE Nix JM. DeVito Ciprofloxacin and norfloxacin, two fluoroquinolone antimicrobials Clin Pharm 6 1987 105 117
68. LC Parish JA. Witkowski The quinolones and dermatologic practice Int J Dermatol 2 1987 351 356
69. WE. Sanders Oral ofloxacin: a critical review of the new drug application Clin Infect Dis 14 1992 539 554
70. RD. Powers Open trial of oral fleroxacin vs amoxicillin/clavulanate in the treatment of infections of skin and soft tissue Am J Med 94 1993 1555 1585
71. JW Smith RL. Nichols Comparison of oral fleroxacin with oral amoxicillin/clavulanate for treatment of skin and soft tissue infections Am J Med 94 1993 1505 1545
72. LO. Gentry Review of quinolones in the treatment of infections of the skin and skin structures J Antimicrob Chemother 28 Suppl C 1991 97 110
73. LO. Gentry Therapy with newer oral β-lactam and quinolone agents for infections of the skin and skin structures: a review Clin Infect Dis 14 1992 285 297
74. LO Gentry CH Ramirez-Ronda E Rodriquez-Noriega Oral ciprofloxacin vs parenteral cefotaxime in the treatment of difficult skin and skin structure infections: a multicenter trial Arch Intern Med 149 1989 2579 2583
75. JR Lentino JB Augustinsky TM Weber Therapy of serious skin and soft tissue infections with ofloxacin administered by intravenous and oral route Chemotherapy 37 1991 70 76
76. JW Smith RL. Nichols Comparison of oral fleroxacin with oral amoxicillin/clavulanate for treatment of skin and soft tissue infections Am J Med 94 Suppl 3A 1993 150S 154S
77. Urinary Tract Infection Study Group Coordinated multicenter study of norfloxacin versus trimethoprim-sulfamethoxazole treatment of symptomatic urinary tract infections J Infect Dis 155 1987 170 177
78. JS Wolfson DC. Hooper Treatment of genitourinary tract infections with fluoroquinolones: activity in vitro, pharmacokinetics and clinical efficacy in urinary tract infections and prostatitis Antimicrob Agents Chemother 33 1989 1655 1661
79. JM Allais LC Preheim TA Tueva Randomized, double-blind comparison of ciprofloxacin and trimethoprim-sulfamethoxazole for complicated urinary tract infections Antimicrob Agents Chemother 32 1988 1320 1330
80. K. Schlakhauser Comparison of IV ofloxacin and piperacillin in the treatment of complicated urinary tract infections J Antimicrob Chemother 26 Suppl D 1990 93 97
81. G Fang C Brennen M Wagener Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective randomized clinical and pharmacokinetic study Antimicrob Agents Chemother 35 1991 1849 1855
82. MT Hessen M Ingerman DH Kaufman Clinical efficacy of ciprofloxacin therapy for gram negative bacillary osteomyelitis Am J Med 82 Suppl 4A 1987 262 265
83. LO Gentry G. Rodriquez-Gomez Ofloxacin versus parenteral therapy for chronic osteomyelitis Antimicrob Agents Chemother 35 1991 538 551
84. LJ Goodman J Segreti GM. Trenholme Fluoro-quinolones in the treatment of infectious diarrhea EW Sanders CC Sanders Fluoroquinolones in the treatment of infectious diseases. 1990 Physicians and Scientists Publishing Glenview (IL) 117 129
85. P Dutta R Rasaily MR Saha Ciprofloxacin for treatment of severe typhoid fever in children Antimicrob Agents Chemother 37 1993 1197 1199
86. AW Dekker M Rozenberg-Arska J. Verhoef Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin Ann Intern Med 106 1987 7 12
87. DL Dworzack CC Sanders EA Horowitz Evaluation of single-dose ciprofloxacin in the eradication of Neisseria meningitidis from nasopharyngeal carriers Antimicrob Agents Chemother 32 1988 1740 1741
88. GE. Stein Drug interactions with fluoroquinolones Am J Med 91 Suppl 6A 1991 81S 86S
89. WJA Wijnands TB Vree CLA. Van Herwaarden The influence of quinolone derivatives on theophylline clearance Br J Clin Pharmacol 22 1986 677 683
90. AK. Kamada Possible interaction between ciprofloxacin and warfarin Drug Intell Clin Pharm 24 1990 27 28
91. HM Jolson A Tanner A Green Adverse reaction reporting of interactions between warfarin and fluoroquinolones Arch Intern Med 151 1991 1003 1004
92. CR. Smith The adverse effects of fluoroquinolones J Antimicrob Chemother 19 1987 709 712
93. MB. Poh-Fitzpatrick Lomefloxacin photosensitivity [letter] Arch Dermatol 130 1994 261
94. Sparfloxacin and levofloxacin Med Lett 39 1997 41 43
95. RT Scheife WR Cramer EL. Decker Photosensitizing potential of ofloxacin Int J Dermatol 32 1993 413 416
96. T Horio H Miyauchi Y Asada Phototoxicity and phototoxicity and photoallergenicity of quinolones in guinea pigs J Dermatol Sci 7 1994 130 135
97. NJ Lowe TD Fakouhi RS Stern T Bourget B Roniker EA. Swabb Photoreactions with a fluoroquinolone antimicrobial: evening vs morning dosing Clin Pharmacol Ther 56 1994 587 591
98. L LeCleach O Chosidu JP Berry Blue black pigmentation of the legs associated with perfloxacin therapy Arch Dermatol 131 1995 856 857
99. Abbott Laboratories Press release June 6, 1992 Abbott Laboratories Abbott Park (IL)
100. P. Sensi History of the development of rifampin Rev Infect Dis 5 Suppl 3 1983 402 406
101. W Wehrli F Krusel K Schmid Interaction of rifamycin with bacterial RNA polymerase Proc Natl Acad Sci U S A 61 1968 667 673
102. C Thornsberry BC Hill JM Swenson Rifampin: spectrum of antibacterial activity Rev Infect Dis 5 Suppl 3 1983 412 417
103. JF. Prescott Rhodococcus equi : an animal and human pathogen Clin Microb Rev 4 1991 20 34
104. RJ O’Brien MA Lyle DE. Snider Rifabutin (Ansamycin LM427): a new rifamycin-S derivative for the treatment of mycobacterial diseases Rev Infect Dis 9 1987 519 530
105. RN Brogden A. Fitton Rifabutin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy Drugs 47 1994 983 1009
106. G. Acocella Pharmacokinetics and metabolism of rifampin in humans Rev Infect Dis 5 Suppl 1983 428 432
107. SD Purohit SK Sarkar ML Gupta Dietary constituents and rifampicin absorption [letter] Tubercle 68 1987 151 152
108. WE Sanders Jr. Rifampin Ann Intern Med 85 1976 82
109. CO Solbeg A Halsens A Digranes Penetration of antibiotics into human leukocytes and dermal suction blisters Rev Infect Dis 5 Suppl 3 1983 468 473
110. ON Gilbert WM. Bennett Use of antimicrobial agents in renal failure Infect Dis Clin North Am 3 1989 517 531
111. NK Tsankov JA. Kamarashev Rifampin in dermatology Int J Dermatol 32 1993 401 406
112. V Ramesh RS Misra V Saxena Comparative efficacy of drug regimens in skin tuberculosis Clin Exp Dermatol 16 1991 106 109
113. JL. Bonate Antibiotiques en pathologie cutanée Rev Med Toulouse 19 1983 29 37
114. DM Hoss HM. Feder Addition of rifampicin to conventional therapy for recurrent furunculosis Arch Dermatol 131 1995 647 648
115. JE Kapusnix F Parenti MA. Sande The use of rifampicin in staphylococcal infections: a review J Antimicrob Chemother 13 Suppl C 1984 61 66
116. RK Joshi PMK. Nambiar Dermal leishmaniasis and rifampicin Int J Dermatol 28 1989 612 614
117. AM Gamea FA. El-Tatawi The effect of rifampicin on rhinoscleroma: an electron microscopic study J Laryngol Otol 104 1990 772 777
118. N Tsankov M. Krasteva Rifampin therapy in severe forms of psoriasis J Dermatol Treat 3 1992 69 71
119. TM Johnson M Duvic RP. Rapin AIDS exacerbation of psoriasis [letter] N Engl J Med 313 1985 1415
120. MS Green JH Prystowsky SR Cohen JI Cohen MG. Lebwohl Infectious complications of erythrodermic psoriasis J Am Acad Dermatol 34 1996 911 914
121. DYM Leung JB Travers R Giorno Evidence for streptococcal superantigen driven process in acute guttate psoriasis J Clin Invest 96 1995 2106 2112
122. F Vincent JB Ross M Dalton A therapeutic trial of the use of penicillin V or erythromycin with or without rifampin in treatment of psoriasis J Am Acad Dermatol 26 1992 458 461
123. LJ Wheat RB Kohler AL White Effect of rifampin on nasal carrier of coagulase-positive staphylococci J Infect Dis 144 1981 177
124. L Bachs A Pares M Elena Effects of long-term rifampicin administration in primary biliary cirrhosis Gastroenterology 102 1992 2077 2080
125. American Thoracic Society/CDD Treatment of tuberculosis and tuberculosis infection in adults and children Ann Rev Respir Dis 134 1986 355 363
126. WS Deen E. Sanders Efficacy of rifampin in treatment of meningococcal carriers N Engl J Med 281 1969 641 645
127. JE Kapusnik F Parenti M. Sande The use of rifampicin in staphylococcal infections review J Antimicrob Chemother 13 1984 61 66
128. M Akova O Uzun HE Akalin Quinolones in treatment of human brucellosis: comparative trial of oxacillin-rifampin versus doxycyline-rifampin Antimicrob Agents Chemother 371 1993 1831 1834
129. SM Borcherding AM Baciewicz TH. Self Update on rifampin drug interactions Arch Intern Med 152 1992 711 716
130. J Grosset S. Leventis Adverse effects of rifampin Rev Infect Dis 5 Suppl 3 1983 S440 S446
131. NC Klein BA. Cunha Tetracyclines Med Clin North Am 79 1995 789 801
132. PJ Neuvonen G Gothoni R Hackman Interference of iron with the absorption of tetracyclines in man Br Med J 4 1970 532 534
133. CD Ericsson S Feldman LK Pickering Influence of subsalicylate bismuth on absorption of doxycyline JAMA 247 1982 2266 2267
134. HC. Standiford Tetracyclines and chloramphenicol 4th ed GL Mandell RG Douglas Jr JE Bennett Principles and practice of infectious disease. 1995 Churchill Livingstone New York 306 317
135. MA Berk AL. Lornicz The treatment of bullous pemphigoid with tetracycline and nicotinamide: a preliminary report Arch Dermatol 122 1986 670 674
136. A Zemtsov KH. Neldner Successful treatment of dermatitis herpetiformis with tetracycline and nicotinamide in a patient unable to tolerate dapsone J Am Acad Dermatol 28 1993 505 506
137. ML Chaffins D Collison DP. Fivenson Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases J Am Acad Dermatol 28 1993 998 1000
138. AC Steere GJ Hutchinson DW Rahn Treatment of the early manifestations of Lyme disease Ann Intern Med 99 1983 22 26
139. RJ Wallace Jr K. Wiss Susceptibility of Mycobacterium marinum to tetracyclines and aminoglycosides Antimicrob Agents Chemother 20 1981 610 612
140. AC Reboli VF. Del Bene Oral antibiotics therapy of dermatologic conditions Dermatol Clin 6 1988 497 520
141. Tetracycline. American Hospital Formulary Service. Drug Information 1995 American Society of Health System Pharmacists Bethesda (MD) 338 355
142. MA Amendda TD. Spera Doxycycline-induced esophagitis JAMA 253 1985 1009 1011
143. MF Elmore JD. Rogge Tetracycline-induced pancreatitis Gastroenterology 81 1981 1134 1136
144. ME. Shils Renal disease and the metabolic effects of tetracycline Ann Intern Med 58 1963 389 408
145. JN Forrest Jr M Cox C Hong Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone N Engl J Med 298 1978 173 177
146. WL Fanning DW Gump RA. Sufferman Side effects of minocycline: a double-blind study Antimicrob Agents Chemother 11 1977 712 717
147. JM Guillon P Joly B Autran Minocycline-induced cells mediated hypersensitivity pneumonitis Ann Intern Med 117 1992 476 481
148. T Matsuura Y Shimizu H Fujimoto Minocycline-related lupus [letter] Lancet 340 1992 1553
149. SR Knowles L Shapiro NH. Shear Serious adverse reactions induced by minocycline: report of 13 patients and review of the literature Arch Dermatol 132 1996 934 939
150. M-J Thibault RC Billick H. Srolovitz Minocycline- induced Sweet’s syndrome J Am Acad Dermatol 27 1992 801 804
151. VL Angeloni SJ Salasche R. Ortiz Nail and scleral pigmentation induced by minocycline Cutis 40 1987 229
152. JP Davies JM. Price-Thomas Gynecomastia in association with minocycline [letter] Br J Clin Pract 49 1995 179
153. J Katz S Barak J Shemer P Langevitz A. Livnek Black tongue associated with minocycline therapy [letter] Arch Dermatol 131 1995 620
154. RH Rubin MN. Schwartz Trimethoprim-sulfamethoxazole N Engl J Med 303 1980 426
155. TS Lundstrom JD. Sobel Vancomcyin, trimethoprim- sulfamethoxazole and rifampin Infect Dis Clin North Am 9 1995 747 767
156. FR Cockerill RS. Edson Trimethoprim- sulfamethoxazole Mayo Clin Proc 66 1991 1260 1269
157. FR Sattler JS. Remington Intravenous trimethoprim- sulfamethoxazole therapy for Pneumocystis carinii pneumonia Am J Med 70 1981 1215 1221
158. RA Smego Jr MB Moeller HA. Gallis Trimethoprim- sulfamethoxazole therapy for nocardia infections Arch Intern Med 143 1983 711 718
159. PG Spitzer SM Hammer AW. Karchmer Treatment of Listeria monocytogenes infection with trimethoprim-sulfamethoxazole: case report and review of the literature Rev Infect Dis 8 1986 427 430
160. RW. Goodgame Understanding intestinal spore-forming protozoa: Cryptosporidia , Microsporidia, Isospora , and Cyclospora Ann Intern Med 124 1996 429 441
161. WL Gold IE. Salit Aeromonas hydrophilia infections of skin and soft tissue: report of 11 cases and review Clin Infect Dis 16 1993 69 74
162. AM. Margileth Antibiotic therapy for cat-scratch disease: clinical study of therapeutic outcome in 268 patients and a review of the literature Pediatr Infect Dis J 11 1992 474 478
163. M Sookprance P Boonma W Susaengrat Multicenter positive randomized trial comparing ceftazidime plus co-trimoxazole with chloramphenicol plus doxycyline and cotrimoxazole for treatment of severe meliodosis Antimicrob Agents Chemother 36 1992 158 162
164. M Magana M. Magana-Garcia Mycetoma Dermatol Clin 7 1989 203 217
165. JA Cotterill WE Cunliffe B. Williamson The effect of trimethoprim-sulfamethoxazole on sebum excretion rate and biochemistry in acne vulgaris Br J Dermatol 85 1971 130 133
166. American Hospital Formulary Service Drug Information 1995 1995 American Society of Health System Pharmacists Bethesda (MD) 560 568
167. R Bissonnette J Tousignant G. Allaire Drug-induced toxic pustuloedema Int J Dermatol 31 1992 172 174
168. DC Walker PR. Cohen Trimethoprim-sulfamethoxazole associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet’s syndrome J Am Acad Dermatol 34 1996 918 923
169. H. Jick Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients Rev Infect Dis 4 1982 426 428
170. RF McGehee Jr CB Smith C Wilcox Comparative studies of antibacterial activity in vitro and absorption and excretion of lincomycin and clindamycin Am J Med Sci 256 1968 279 292
171. ME Falagas SL. Gorbach Clindamycin and metronidazole Med Clin North Am 79 1995 845 867
172. VL. Sutter In vitro susceptibility of anaerobes: comparison of clindamycin and other antimicrobial agents J Infect Dis 135 Suppl 1977 S7 S12
173. B Dannemann JA McCutchan D Israelski Treatment of toxoplasmic encephalitis in patients with AIDS: a randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazene. The California Collaborative Treatment Group Ann Intern Med 116 1992 33 43
174. Centers for Disease Control Clindamycin and quinine treatment for Babesia microti infections MMWR Morb Mortal Wkly Rep 32 1983 65 72
175. PG Kremsner S Winkler TC Brand Curing of chloroquine-resistant malaria with clindamycin Am J Trop Med Hyg 49 1993 650
176. JO Panzer DC Brown WL Epstein Clindamycin levels in various body tissues and fluids J Clin Pharmacol 12 1972 259
177. MS Klempner B. Styrt Prevention of recurrent staphylococcal skin infections with low dose oral clindamycin therapy JAMA 260 1988 2682
178. JD Smilack WR Wilson FR. Cockerill Tetracyclines, chloramphenicol, erythromycin, clindamycin, and metronidazole Mayo Clin Proc 66 1991 1270 1280
179. Clindamycin. American Hospital Formulary Service. Drug Information 1995 American Society of Health System Pharmacists. 1995 357 361
180. JG. Bartlett Antimicrobial agents implicated in Clostridium difficile toxin associated diarrhea or colitis Johns Hopkins Med J 149 1981 6 9
181. VK Dhawan H. Thadepalli Clindamycin: a review of fifteen years of experience Rev Infect Dis 4 1982 1133 1153